We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Orchard

News List

Orchard’s OTL-101 receives promising medicine designation for ADA-SCID in UK pharmaceutical-technology
August 24, 2017
Biotechnology company Orchard Therapeutics’ OTL-101 has received a promising innovative medicine designation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of adenosine deaminase severe combined immunodeficiency.
Orchard Therapeutics signs manufacturing services agreement with PCT Cell Therapy Services cphi-online
June 02, 2017
Under the terms of this new agreement, PCT will provide GMP-compliant manufacturing services for Orchard’s lead product, OTL-101, an autologous ex-vivo gene therapy for the treatment of ADA-SCID.

Previous page 1 2 Next page